Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus

Tsuchiya, Naoyuki; Shiota, M; Yamaguchi, Akihiro; Itō, Kōji

doi:10.1002/art.1780390511

Cited by 45 publications

(29 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An increased serum concentration of sHLA-I in patients with systemic lupus erythematosus (SLE), a multisystemic autoimmune disease which primarily affects middle-aged women, has also been previously reported [15][16] and sHLA-I has been suggested to be a useful marker of disease activity in SLE [17]. It has been shown that in patients suffering from autoimmune diseases other than SLE, such as rheumatoid arthritis, polymyositis/dermatomyositis or systemic sclerosis no significant elevation of sHLA-I could be demonstrated [18].…”

Section: Introductionmentioning

confidence: 91%

Increased Level of Soluble HLA Class I Antigens in Systemic Lupus Erythematosus: Correlation with Anti-DNA Antibodies and Leukopenia

Kippner

Klint²,

Sturfelt

et al. 2001

Journal of Autoimmunity

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 91%

Increased Level of Soluble HLA Class I Antigens in Systemic Lupus Erythematosus: Correlation with Anti-DNA Antibodies and Leukopenia

Kippner

Klint²,

Sturfelt

et al. 2001

Journal of Autoimmunity

View full text Add to dashboard Cite

“…It has been known for a while that the levels of the soluble HLA class I molecules (sHLA-I) are elevated in the serum of people inflicted with diseases, such as cancer (9)(10)(11)(12)(13), autoimmunity (14), allergy (15), and viral infections (16). Such elevated levels of sHLA were even proposed to serve as indicators of poor prognosis (11,17), yet their bound peptidomes have never been analyzed before.…”

mentioning

confidence: 99%

Soluble plasma HLA peptidome as a potential source for cancer biomarkers

Bassani-Sternberg

Barnea

Beer

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

120

133

View full text Add to dashboard Cite

The HLA molecules are membrane-bound transporters that carry peptides from the cytoplasm to the cell surface for surveillance by circulating T lymphocytes. Although low levels of soluble HLA molecules (sHLA) are normally released into the blood, many types of tumor cells release larger amounts of these sHLA molecules, presumably to counter immune surveillance by T cells. Here we demonstrate that these sHLA molecules are still bound with their authentic peptide repertoires, similar to those of the membranal HLA molecules (mHLA). Therefore, a single immunoaffinity purification of the plasma sHLA molecules, starting with a few milliliters of patients' blood, allows for identification of very large sHLA peptidomes by mass spectrometry, forming a foundation for development of a simple and universal blood-based cancer diagnosis. The new methodology was validated using plasma and tumor cells of multiple-myeloma and leukemia patients, plasma of healthy controls, and with cultured cancer cells. The analyses identified thousands of sHLA peptides, including some cancer-related peptides, present among the sHLA peptidomes of the cancer patients. Furthermore, because the HLA peptides are the degradation products of the cellular proteins, this sHLA peptidomics approach opens the way for investigation of the patterns of protein synthesis and degradation within the tumor cells.

show abstract

“…NKT cells were stimulated to produce IFN-Á in the presence of sCD1d mixed with lipids antigens (·-GalCer). Previous studies (24,25) demonstrated soluble HLA class I molecules (sHLAs) in sera from patients with RA, SLE, and multiple sclerosis. These soluble HLAs acted by binding to TCR on alloreactive T cells (26).…”

Section: Discussionmentioning

confidence: 99%

Low levels of soluble CD1d protein alters NKT cell function in patients with rheumatoid arthritis

Segawa

Goto²,

Yoshiga³

et al. 2009

Int J Mol Med

View full text Add to dashboard Cite

Abstract. CD1d molecules on the cell surface play a critical role in the presentation of glycolipid antigens to natural killer T (NKT) cells. We previously showed that the human CD1d gene has 8 splice variants, one of which is a soluble form lacking the ß2-m and transmembrane domains. This study focused on soluble CD1d (sCD1d) by generating recombinant sCD1d proteins and assaying them in plasma using a newly established ELISA method. The amount of sCD1d proteins in plasma was significantly decreased in rheumatoid arthritis (RA) patients (55.2±13.3 years, mean ±SD) compared with healthy donors (31.2±7.4 years). Plasma sCD1d protein levels correlated with the number of NKT cells (TCR V·24 + Vß11 + CD3 + ) in peripheral blood mononuclear cells (r 2 =0.061). Furthermore, sCD1d proteins induced IFN-Á production from NKT cells, but neither IL-4 nor IL-10. These findings suggest that the low plasma levels of sCD1d protein in RA patients reduce the number and thus activation of peripheral NKT cells. It is therefore hypothesized that sCD1d stimulates NKT cells and low plasma sCD1d levels in RA reflect a pathogenic mechanism associated with a decrease in NKT cells.

show abstract

Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus

Cited by 45 publications

References 12 publications

Increased Level of Soluble HLA Class I Antigens in Systemic Lupus Erythematosus: Correlation with Anti-DNA Antibodies and Leukopenia

Increased Level of Soluble HLA Class I Antigens in Systemic Lupus Erythematosus: Correlation with Anti-DNA Antibodies and Leukopenia

Soluble plasma HLA peptidome as a potential source for cancer biomarkers

Low levels of soluble CD1d protein alters NKT cell function in patients with rheumatoid arthritis

Contact Info

Product

Resources

About